Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2025-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
2024年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2024 by 亿帆医药股份有限公司. It contains specific financial data such as balances, amounts, interest, and repayments related to related parties and subsidiaries. The document is relatively short (2815 characters) and focuses on a specific financial aspect rather than a comprehensive financial report or announcement. It does not appear to be an annual report, interim report, earnings release, or any form of meeting material. It is a financial disclosure related to related party transactions, which typically falls under regulatory filings or specific audit-related disclosures. However, since it is a summary table of related party fund occupation and transactions, it aligns best with Regulatory Filings (RNS) as it does not fit the definitions of other more specific categories and is a compliance disclosure.
2025-04-27 Chinese
关于公司及控股公司向金融机构申请授信额度及公司合并报表范围内担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company (亿帆医药股份有限公司) regarding its application for credit facilities from financial institutions and the provision of guarantees within its consolidated financial statement scope. It includes specific financial figures, guarantee limits, asset-liability ratios, and detailed information about subsidiaries and their financial status. The document is an announcement about financing and guarantee arrangements, not a full financial report or audit report. It does not contain comprehensive financial statements or management discussion and analysis but focuses on capital/financing updates related to credit and guarantee limits. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7639 characters) and content confirm it is a substantive announcement rather than a brief notice or certification, supporting this classification with high confidence.
2025-04-27 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" which translates to "2024 Supervisory Board Work Report". It details the supervisory board's activities, meetings, opinions on financial reports, internal controls, related party transactions, and plans for 2025. It references the company's annual report, quarterly reports, and audit opinions but does not itself contain full financial statements or detailed financial data. The document is a formal report from the supervisory board summarizing oversight activities and opinions rather than the full annual report or audit report. It is not a short announcement or certification but a substantive supervisory board report. This type of document fits best under the category of Management Reports (MDA), which includes management's detailed explanations and oversight reports related to financial results and business trends.
2025-04-27 Chinese
关于2024年度计提资产减值准备的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by 亿帆医药股份有限公司 regarding the 2024 fiscal year asset impairment provisions. It details the amounts of impairment for various asset categories, the accounting standards applied, and the impact on the company's financial results. The document includes board and supervisory committee approvals and audit confirmation by an accounting firm. The length is about 3008 characters, which is relatively short but contains substantive financial data and detailed analysis of asset impairment provisions for the fiscal year 2024. It is not merely an announcement of a report publication but contains actual financial figures and explanations. Therefore, it is a financial disclosure related to asset impairment provisions, which is typically part of an Interim/Quarterly Report or Annual Report. However, since it focuses specifically on asset impairment provisions for the fiscal year 2024 and is not a full annual report, it fits best under Regulatory Filings (RNS) as a specific announcement of impairment provisions rather than a full Annual Report (10-K) or Interim Report (IR). The document is regulatory in nature and does not fit other categories like Earnings Release or Audit Report standalone. Hence, the best classification is Regulatory Filings (RNS).
2025-04-27 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2024 年年度报告摘要' which translates to '2024 Annual Report Summary'. It contains detailed financial data for the year 2024, including total assets, net profit, earnings per share, and other key financial indicators. It also includes comprehensive business descriptions, product information, industry analysis, shareholder information, and corporate governance details. The document is over 10,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of detailed financial statements and management discussion aligns with the characteristics of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, and it is not a quarterly or interim report. Therefore, the document should be classified as an Annual Report (10-K). FY 2024
2025-04-27 Chinese
关于董事会、监事会延期换届的提示性公告
Board/Management Information Classification · 95% confidence The document is a public announcement from a company regarding the postponement of the board of directors and supervisory board re-election. It discusses governance structure, board term expiration, and continuity of management duties. There is no financial data, no mention of financial results, no audit information, no voting results, and no regulatory certifications. The content is about board and management information, specifically about changes or delays in board elections and governance matters. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear governance-related content.
2025-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.